Technology evaluation: BLP-25, Biomira Inc.

Technology evaluation: BLP-25, Biomira Inc. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Technology evaluation: BLP-25, Biomira Inc. Abstract Text:

M A Morse,

Biomira is developing the MUC-1 peptide-based vaccine BLP-25 for the potential treatment of cancer. It is in phase II trials for non-small cell lung cancer (NSCLC) [335997], [353448], [384703]. The MUC-1 mucin secreted by cancer cells has been shown to decrease the activity of certain immune response cells, including killer T-cells, and can inhibit the immune T-cell response by > 70%. BLP-25 is designed to target an immune response to the MUC-1 mucin that is shown by > 90% of common solid tumors. The introduction of IL-2 reverses the T-cell suppression caused by MUC-1 mucin, and enhances the cellular immune response > 100-fold. Biomira has been incorporating IL-2 into a liposomal delivery system for BLP-25 [274576]. In late 1998, Biomira entered into a research collaboration with Axis Genetics. The collaboration will assess the further potential of therapeutic cancer vaccines against MUC-1. Each company has developed a vaccine targeting the MUC-1 peptide and Biomira will be evaluating Axis's vaccine in preclinical trials [313395]. In December 1996, Biomira signed a licensing agreement whereby it was granted the rights to use Dana-Farber Cancer Institute's two US patents relating to MUC-1 (based on pioneering work at the Institute on the identification of cell-surface molecules that are characteristic of cancer cells) for peptide-based cancer vaccines [228101].

Technology evaluation: BLP-25, Biomira Inc. Publishing Authors By Initials

MA Morse,

For similar peptides: peptide fragments research abstracts see: peptides: peptide fragments research

PUBMED ID PMID:

MEDLINE DATE:

Technology evaluation: BLP-25, Biomira Inc. Journal Published:

PUBLICATION TYPE: Review

Journal: Current opinion in molecular therapeutics

VOLUME: 3

Page Numbers: 102-5

Journal Abbreviation: Curr. Opin. Mol. Ther.

ISSN: 1464-8431

DAY: 1

MONTH: Feb

YEAR: 2001

Technology evaluation: BLP-25, Biomira Inc. Information

Number of References: 24

LANGUAGE: eng

NlmUniqueID: 100891485

Technology evaluation: BLP-25, Biomira Inc. Keywords Mesh Terms:

KEYWORDS: Peptide Fragments

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Technology evaluation: BLP-25, Biomira Inc. Information

Substance Name: Peptide Fragments

Registry Number: 0

Grant and Affiliation Information for Technology evaluation: BLP-25, Biomira Inc.

AFFILIATION: Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. m.morse@cgct.duke.edu

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Curr Opin Mol Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Technology evaluation: BLP-25, Biomira Inc Related Publications

• A dinoflagellate AAA family member rescues a conditional yeast G1/S phase cyclin mutant through increased CLB5 accumulation.
• Advances in pharmacogenomics of antiretrovirals: an update.
• Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells.
• Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.
• Bone morphogenetic protein receptor 2 mutations in pulmonary hypertension.
• Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users.
• Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks.
• Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry.
• Direct selection of RNA beacon aptamers.
• Drug interactions between proton pump inhibitors and antiretroviral drugs.
• Duplicate publication.
• Effects of pyriproxyfen on California red scale (Hemiptera: Diaspididae) development and reproduction.
• Functional deficiency in IL-7 caused by an N-ethyl-N-nitrosourea-induced point mutation.
• Genome-wide analysis of transcriptional dependence and probable target sites for Abf1 and Rap1 in Saccharomyces cerevisiae.
• Global infectious disease surveillance and health intelligence.
• Global preparedness for public health emergencies.
• HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countries.
• Hierarchical assembly of the siliceous skeletal lattice of the hexactinellid sponge Euplectella aspergillum.
• High resolution Fourier-domain optical coherence tomography of retinal angiomatous proliferation.
• Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application.
• Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.
• Pandemic influenza: studying the lessons of history.
• Rotationally resolved spectroscopy of jet-cooled NbMo.
• Simulations of dynamics and viscoelasticity in highly entangled solutions of semiflexible rods.
• Technology evaluation: BLP-25, Biomira Inc.
• The US pandemic influenza implementation plan at six months.
• Toxicity of systemic neonicotinoid insecticides to avocado thrips in nursery avocado trees.
• Transcription factor access to promoter elements.
• Use of the finite element method to assess impact of current on forearm and wrist during an electrical accident.
• Wide dynamic range germanium detector for perturbation crystallography.